Current perspective on antiresorptive therapies in osteoporosis

Yıl 2025, Cilt: 47 Sayı: 4, 655 - 665, 18.06.2025

Aysen Akalın

Öz

Antiresorptive drugs act by suppressing bone turnover and reduce the risk of fracture by increasing the amount of bone over time. Today, the main antiresorptive drugs with indications for use in the treatment of osteoporosis are bisphosphonates, denosumab, and a selective estrogen receptor modulator(SERM), raloxifene. Bisphosphonates are used as first-line drugs in the treatment of osteoporosis and reducing the risk of fractures. Bisphosphonates accumulate in bone and their effects on bone turnover may persist for years after discontinuation of the drug. The most important side effects that can be seen in patients using bisphosphonates associated with long-term suppression of bone turnover are osteonecrosis of the jaw and atypical femur fractures. It is possible to prevent these problems by not using bisphosphonates continuously for a long time without interrupting the treatment in patients with low fracture risk. Denosumab inhibits bone turnover by impairing osteoclast functions. It increases the bone mineral density (BMD) and provides reduction in fracture risk. One of the drawbacks with the use of denosumab is the rapid decrease in effects on bone and an increased risk of bone loss and fracture after discontinuation of treatment. Denosumab should not be discontinued or the treatment be continued with a different antiresorptive such as bisphosphonates. Although denosumab can be used in patients with renal failure, it has a high risk of causing hypocalcemia. Of the selective estrogen receptor blockers (SERMs), only raloxifene is currently used very limitedly in the treatment of osteoporosis. Although raloxifene increases bone mineral density in the spine and hip and reduces the risk of vertebral fractures, its effect on non-vertebral fractures has not been demonstrated. Since it has a strong antiestrogenic effect in the breast, it may reduce the risk of invasive breast cancer in estrogen receptor (ER) positive patients. Raloxifene has a limited indication for use in the treatment of osteoporosis in postmenopausal women at high risk for invasive breast cancer, as well as in postmenopausal women who are intolerant or unsuitable for bisphosphonates and do not have a fragility fracture.

Anahtar Kelimeler

osteoporosis , antiresorptive , therapy

Osteoporozda antirezorptif tedavilere güncel yaklaşım

Öz

Antirezorptif ilaçlar kemik döngüsünü baskılayarak etkinlik gösteren ve zamanla kemik miktarında artışa neden olarak kırık riskini azaltan bir ilaç grubudur. Günümüzde osteoporoz tedavisinde kullanım endikasyonu bulunan başlıca antirezorptif ilaçlar bisfosfonatlar, denosumab ve selektif östrojen reseptör modülatörlerinden raloksifendir. Bisfosfonatlar osteoporozun tedavisinde ve kırık riskini azaltmada ilk basamak olarak kullanılır. Kemikte birikime uğrarlar ve kemik döngüsü üzerindeki etkileri ilacın kesilmesinden sonra yıllarca sürebilir. Kemik döngüsünün uzun süreli baskılanmasına bağlı bisfosfonat kullanan hastalarda görülebilen en önemli yan etkiler çene kemiği osteonekrozu ve atipik femur kırıklarıdır. Kırık riski düşük olan hastalarda bisfosfonatların aralıksız uzun süre kullanılmamaları ve tedaviye ara verilmesi ile bu sorunların önlenmesi mümkündür. Denosumab osteoklast fonksiyonlarını bozarak kemik döngüsünü inhibe eder. Kemik miktarını artırır ve kırık riskinde azalma sağlar. Denosumab ile ilgili çekincelerden birisi tedavinin kesilmesini takiben kemik üzerindeki etkilerin hızla azalması ve kemik kütlesinde kayıp ve kırık riskinde artış olmasıdır. Denosumab tedavisine ara verilmemesi veya tedavinin kesilmesini takiben bisfosfonatlar gibi farklı bir antirezorptif ile tedaviye devam edilmesi bu riski azaltabilir. Denosumab renal yetmezlikli hastalarda kullanılabilirse de hipokalsemiye yol açma riski yüksektir. Selektif östrojen reseptör blokerlerinden(SERM) sadece raloksifen günümüzde osteoporoz tedavisinde çok kısıtlı olarak kullanılmaktadır. Raloksifen vertebra ve kalçada kemik mineral yoğunluğunda artış sağlar ve vertebra kırık riskini azaltırsa da vertebra dışı kırıklar üzerine etkisi gösterilememiştir. Memede güçlü antiöstrojenik etki gösterdiğinden östrojen reseptörü(ER) pozitif hastalarda invaziv meme kanseri riskinde azalma sağlayabilir. Raloksifenin invaziv meme kanseri riski yüksek olan ve yanı sıra bisfosfonatları tolere edemeyen veya bu tedavilere uygun olmayan ve frajilite kırığı bulunmayan postmenopozal kadınlarda osteoporozun tedavisinde sınırlı bir kullanım endikasyonu vardır.

Anahtar Kelimeler

osteoporoz , antirezorptif , tedavi

Kaynakça

• 1. Arceo-Mendoza RM, Camacho PM. Postmenopausal osteoporosis: Latest Guidelines Endocrinol Metab N Am 2021;50:167-178.
• 2. Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nature Reviews Endocrinology 2012:8; 81-91.
• 3. Fleisch H. Bisphosphonates: Mechanisms of action. Endocrine Reviews 1998;19(1): 89-100.
• 4. Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab N Am 2012; 41: 487-506.
• 5. McClung MR. Bisphosphonates. Endocrinol Metab N Am 2003: 32; 253-271.
• 6. Fleisch H. Bisphosphonates: pharmacology. Semin Arthritis Rheum 1994;23(4):261-262.
• 7. Reid IR, Horne AM, Mihov B, Gamble GD. Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Calcif Tissue Int 2017; 101:371.
• 8. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95(4):1555-65.
• 9. Rizzoli R. Bisphosphonates for postmenopausal osteoporosis: are they all the same? QJM 2011;104(4):281-300.
• 10. Chen, J. S. & Sambrook, P. N. Antiresoptive therapies for osteoporosis: A Clinical overwiev. Nat Rev Endocrinol 2012; 8: 81–91.
• 11. De Paula F.J.A,Black D.M, Rosen C.R: Osteoporosis:Basic and Clinical aspects. In: Williams Textbook of Endocrinology, Melmed S, Auchus R.J, Goldfine A.B, Koenig R.J, Rosen C.J (eds). 14th ed. Philadelphia:Elsevier, Inc. 2020:1256-97.
• 12. Zhang J, Saag KG, Curtis JR. Long-term safety concerns of antiresorptive therapy. Rheum Dis Clin N Am 2011; 37:387-400.
• 13. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003; 348:1503.
• 14. Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ 2012; 184:E431.
• 15. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30:3.
• 16. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008; 121:475.
• 17. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479.
• 18. Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 2022; 80:920.
• 19. Adler R. Update on rare advers events from osteoporosis therapy and bisphophonate drug holidays. Endocrinol Metab Clin N Am 2021; 50:193-203
• 20. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25:2267.
• 21. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29:1.
• 22. Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 2007;20:186.
• 23. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809.
• 24. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation systematic review and meta-analysis. Drug Saf 2009;32:219.
• 25. Barrett-Connor E, Swern AS, Hustad CM, et al. Alendronate and atrial fibrillation:a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012;23:233.
• 26. Anastasilakis A, Toulis KA, Anastasilakis CD, Makras P. Long-term treatmant of osteoporosis: safety and efficacy appraisal of denosumab. Therapeutics and Clinical Risk management 2012; 8: 295-306.
• 27. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8): 756–65.
• 28. Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 2015;26(12):2773–83.
• 29. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5(7):513–23.
• 30. Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther 2022;39(1):58-74.
• 31. Zeytinoğlu M, Naaman SC, Dickens LT. Denosumab discontinuation in patients treated for low bone density and osteoporosis. Endocrinol Metab Clin N Am 2021; 50:205-222.
• 32. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy:a randomized blinded phase 2 clinical trial. Bone 2008;43(2):222-229.
• 33. Saul D, Drake MT. Update on approved osteoporosis therapies including combination and sequential use of agents. Endocrinol metab N Am 2021; 50:179-191.
• 34. Geller M, Wagman RB, Ho PR, Siddhanti S, Stehman-Breen C,Watts NB, Papapoulos S. Early findings from Prolia post marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis. Osteoporosis International 2014; 25(Supplement 2): 56–57.
• 35. Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med 2009; 361:818.
• 36. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011; 26:1829.
• 37. Rachner TD, Platzbecker U, Felsenberg D, Hofbauer LC. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc 2013; 88:418.
• 38. Cating-Cabral MT, Clarke BL. Denosumab and atypical femur fractures. Maturitas 2013; 76:1.
• 39. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93:2149.
• 40. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 23; 354 (8):821-31.
• 41. Ettinger B, Black D M, Mitlak B H, Knickerbocker R K, Nickelsen TGenant H K Cummings S R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA;1999:282(7), 637–645.
• 42. Barrett-Connor, E. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–137.
• 43. Adomaityte J, Farooq M, Qayyum, R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 2008; 99, 338–342.